Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Mead Johnson Nutrition

Related MJN
Zimmer Posts Q2 Earnings Beat, Revenues Miss; Guides Low
Boston Scientific Tops Q2 Earnings, Revenues; Ups EPS View

In a report published Friday, Deutsche Bank reiterated its Buy rating on Mead Johnson Nutrition (NYSE: MJN), and raised its price target from $77.00 to $81.00.

Deutsche Bank noted, “Affirm BUY Opinion - In the face of building pessimism in late 2012 and into 2013, we maintained an optimistic view on Mead. With broad share gains in a typically rational and highly profitable category, the LT outlook remains bright. With an eventual U.S. recovery, non-China EM markets ramping up and good prospects in China/HK along with a reasonable global CPG valuation, we retain our BUY.”

Mead Johnson Nutrition closed on Thursday at $76.00.

Latest Ratings for MJN

DateFirmActionFromTo
Jul 2014CitigroupMaintainsBuy
Jul 2014Credit SuisseMaintainsOutperform
Jul 2014Deutsche BankMaintainsBuy

View More Analyst Ratings for MJN
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (MJN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters